GLP-1 and SGLT-2 Drugs Linked to Shifting Autoimmune Disease Risks in Large Study
A large records analysis finds newer diabetes drugs carry differing autoimmune risk profiles, with DPP-4 inhibitors standing out most.
Summary
Researchers analyzed hundreds of thousands of patient records to compare autoimmune disease risks among three classes of newer diabetes medications: GLP-1 receptor agonists, SGLT-2 inhibitors, and DPP-4 inhibitors. The study, published in ACR Open Rheumatology, found that DPP-4 inhibitors carried notably higher risks for bullous pemphigoid and dermatomyositis compared to both other drug classes, while GLP-1 drugs were linked to higher rates of psoriasis, psoriatic arthritis, and autoimmune thyroiditis than DPP-4 inhibitors. GLP-1 and SGLT-2 drugs showed no significant differences across all 19 autoimmune conditions examined. Researchers caution these are preliminary signals, not confirmed causal relationships, and call for deeper mechanistic studies.
Detailed Summary
As GLP-1 receptor agonists and SGLT-2 inhibitors become increasingly common diabetes and weight-management therapies, understanding their immunological effects is critical for millions of long-term users. Yet very little research had previously examined how these newer drug classes affect autoimmune disease risk. A new study from Harvard Medical School and Brigham and Women's Hospital attempts to fill that gap.
Published in ACR Open Rheumatology, the analysis by Dr. Jeffrey Sparks and colleagues examined large-scale medical records to compare rates of 19 autoimmune conditions among new users of DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors. The comparison revealed meaningful differences primarily involving DPP-4 inhibitors versus the other two classes.
DPP-4 inhibitors were associated with roughly double the risk of bullous pemphigoid and dermatomyositis compared to both GLP-1 and SGLT-2 drugs, and nearly double the risk of giant cell arteritis versus SGLT-2 inhibitors. Conversely, patients on DPP-4 inhibitors showed lower rates of plaque psoriasis, psoriatic arthritis, and autoimmune thyroiditis compared to GLP-1 agonist users. Notably, GLP-1 and SGLT-2 inhibitors showed no statistically significant differences across any of the 19 autoimmune conditions studied.
For several conditions including rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis, and celiac disease, no significant between-class differences were observed at all. Researchers noted that some findings align with prior reports, such as DPP-4 inhibitors' known ability to suppress thyroid inflammation triggered by lymphocytes.
Critically, the authors stop well short of claiming these drugs cause autoimmune disease. They describe the findings as preliminary signals intended to guide future mechanistic research. For health-conscious individuals or patients currently on any of these medications, the findings suggest it is worth discussing autoimmune monitoring with a physician, particularly for those on DPP-4 inhibitors who may have elevated skin and muscle disease risk.
Key Findings
- DPP-4 inhibitors carried roughly double the risk of bullous pemphigoid and dermatomyositis versus GLP-1 and SGLT-2 drugs.
- GLP-1 agonists were linked to higher rates of psoriasis, psoriatic arthritis, and autoimmune thyroiditis than DPP-4 inhibitors.
- GLP-1 and SGLT-2 inhibitors showed no significant autoimmune risk differences across all 19 conditions examined.
- No significant differences were found between any drug class for RA, lupus, MS, IBD, or celiac disease.
- Authors classify findings as preliminary signals requiring mechanistic follow-up, not confirmed causal links.
Methodology
This is a news report summarizing a peer-reviewed observational study published in ACR Open Rheumatology by Harvard-affiliated researchers. The study used a large retrospective medical records database comparing new-onset autoimmune diagnoses across three antidiabetic drug classes. Observational design limits causal inference; confounding by indication is a significant concern.
Study Limitations
The observational design cannot establish causation and is vulnerable to confounding by indication, channeling bias, and unmeasured variables. The article is a secondary news summary and does not include full methodology details; primary source review in ACR Open Rheumatology is recommended. Findings are described by the authors themselves as preliminary signals requiring further mechanistic investigation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: